Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: A randomized, single-blind, placebo-controlled study | PLOS ONE
![Study design for administration of denosumab to patients with giant... | Download Scientific Diagram Study design for administration of denosumab to patients with giant... | Download Scientific Diagram](https://www.researchgate.net/publication/346136653/figure/fig1/AS:990791807803393@1613234583955/Study-design-for-administration-of-denosumab-to-patients-with-giant-cell-tumor-of-the.png)
Study design for administration of denosumab to patients with giant... | Download Scientific Diagram
![Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study - The Lancet Oncology Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/cd1e1758-4322-430d-bf36-cc8dc1363d2b/gr1_lrg.jpg)
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study - The Lancet Oncology
![Vertebral fractures after denosumab discontinuation in breast cancer survivors---a single institution experience - Authorea Vertebral fractures after denosumab discontinuation in breast cancer survivors---a single institution experience - Authorea](https://authorea.com/users/345750/articles/471877-vertebral-fractures-after-denosumab-discontinuation-in-breast-cancer-survivors-a-single-institution-experience/master/file/figures/image1/image1.png?1596755742)
Vertebral fractures after denosumab discontinuation in breast cancer survivors---a single institution experience - Authorea
![Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. - Abstract - Europe PMC Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6613724/bin/coonc-31-329-g001.jpg)
Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. - Abstract - Europe PMC
![Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study - ScienceDirect Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2473952921000975-fx1.jpg)
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study - ScienceDirect
![What You Should Know about Denosumab (Prolia) for Increasing Bone Mass during Breast - The ASCO Post What You Should Know about Denosumab (Prolia) for Increasing Bone Mass during Breast - The ASCO Post](https://ascopost.com/media/152338/3.2.48_chart.jpg)
What You Should Know about Denosumab (Prolia) for Increasing Bone Mass during Breast - The ASCO Post
![Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial - The Lancet Diabetes & Endocrinology Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/attachment/de4069cd-afe5-441f-a714-97595f412c53/gr1.gif)
Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial - The Lancet Diabetes & Endocrinology
![Evaluation of denosumab in adult oncology patients for the prevention of skeletal related events across a large academic health system - Michelle R. Sproat, Bradley Burton, Catherine Burdalski, Timothy Porter, Celia Proctor, Evaluation of denosumab in adult oncology patients for the prevention of skeletal related events across a large academic health system - Michelle R. Sproat, Bradley Burton, Catherine Burdalski, Timothy Porter, Celia Proctor,](https://journals.sagepub.com/cms/10.1177/10781552211052514/asset/images/large/10.1177_10781552211052514-fig2.jpeg)
Evaluation of denosumab in adult oncology patients for the prevention of skeletal related events across a large academic health system - Michelle R. Sproat, Bradley Burton, Catherine Burdalski, Timothy Porter, Celia Proctor,
![The Emerging Role of Denosumab in the Long-Term Management of Parathyroid Carcinoma-Related Refractory Hypercalcemia - Endocrine Practice The Emerging Role of Denosumab in the Long-Term Management of Parathyroid Carcinoma-Related Refractory Hypercalcemia - Endocrine Practice](https://www.endocrinepractice.org/cms/asset/033301f1-7d29-455b-8797-05477134f459/fx1.jpg)
The Emerging Role of Denosumab in the Long-Term Management of Parathyroid Carcinoma-Related Refractory Hypercalcemia - Endocrine Practice
![Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer | Prostate Cancer and Prostatic Diseases Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer | Prostate Cancer and Prostatic Diseases](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41391-018-0060-y/MediaObjects/41391_2018_60_Fig1_HTML.jpg)